Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... NY (PRWEB) May 17, 2013 ... Topical BioMedics, Inc., has been listed among nationally ... in an initiative conducted by "U.S. News" Health ... has earned the “No. 1 Pharmacists Recommended ... 17 other national OTC brands, and is the ...
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine and Professor ... Einstein College of Medicine and Associate Chairman of the ... He is also Associate Director for Clinical Research at ... Cancer Working Group, a multidisciplinary group of physicians and ... serves as Vice Chair of the National Cancer Institute ...
(Date:5/17/2013)... Oven Industries Inc. announces a new temperature ... has many user-friendly benefits. Contained all in one enclosure, ... a self-contained temperature control system, which has ... device unique, as well as highly convenient for users. ... universally, which allows the user to use the device ...
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3New Temperature Control Products Announced by Oven Industries Inc. 2
... Accelerate Customer Development Programs; Agreement Underscores SAFC,s Commitment to Japan ... April 28 SAFC Hitech (R), a ... (Nasdaq: SIAL ), today underlined its commitment to ... partnership with leading industrial and medical gas producer, ...
... Phase 1 healthy volunteer study of IMX942 will provide ... 28 /PRNewswire/ - Inimex Pharmaceuticals is pleased to announce ... administered to human subjects for the first time on ... a Phase 1 safety study of IMX942 being performed ...
... pain palliation as an acceptable primary endpoint, ... approval,BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... company has reached an agreement with the U.S. Food ... second Phase 3 registration trial of OGX-011, its lead ...
Cached Biology Technology:SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 2SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 3SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 4SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 5Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) ... diet and lifestyle. , Individuals suffering from ... strength, fatigue and poor quality of life. These ... remission. A randomized, double blind, placebo-controlled study found ... corresponded to significant relief of these symptoms. ...
(Date:5/18/2013)... FL (May 18, 2013) An increasing number ... require interventions to resolve, according to research presented ... one study targeting obesity, researchers at the Cleveland ... a unique pattern of exhaled breath compared to ... volatile organic compound levels that can be correlated ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3
... the University at Buffalo have received a $2.5 million ... heart dysfunction called "hibernating myocardium" that can cause disabling ... is a condition in which myocytes (cells in the ... areas that receive reduced blood flow over an extended ...
... identified a new genus of a living primate from Africa, ... in the online Science Express. , "This is exciting ... by no means over," says William Stanley, a co-author of ... where the world's only specimen of this forest-dwelling monkey "resides" ...
... within cells may underlie several adult-onset neurodegenerative diseases, such ... cell transport is blocked in these diseases may offer ... published online June 4 in Nature Neuroscience, researchers from ... showed how a chemical pathway that is obstructed in ...
Cached Biology News:Reversing 'hibernating' heart muscle focus of UB researchers 2Scientists describe new African monkey genus ?first in 83 years 2Scientists describe new African monkey genus ?first in 83 years 3Mechanism for neurodenegerative diseases linked to transport proteins 2
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... a small and sensitive single quadrupole ... LC and IC. It features a newly ... (API) source for outstanding sensitivity and noise ... existing LC and IC methods, especially those ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
Biology Products: